Deucravacitinib vs Ustekinumab for Plaque Psoriasis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores two treatments, Deucravacitinib and Ustekinumab, to determine which is safer for individuals with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. The goal is to assess the long-term safety of these treatments. Individuals with psoriasis requiring special light therapy or medication, and who have cardiovascular risks such as smoking, diabetes, or high blood pressure, might be suitable candidates for this trial. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of new treatments.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Previous studies have shown that deucravacitinib remains consistently safe over five years for people with moderate to severe plaque psoriasis. Although some patients experienced infections, no new safety issues emerged. In contrast, ustekinumab has been used for over 14 years and is considered safe compared to other psoriasis treatments. The FDA has approved it for moderate to severe plaque psoriasis. Both treatments have a long history, with no major safety surprises reported in recent years.12345
Why are researchers excited about this trial's treatments?
Deucravacitinib is unique because it targets the TYK2 enzyme, a part of the immune system pathway involved in inflammation, which is different from many current psoriasis treatments that often target other parts of the immune system. This new mechanism of action might offer better results for patients who don't respond well to traditional therapies like methotrexate or TNF inhibitors. Researchers are excited about its potential to provide a more targeted approach with possibly fewer side effects and improved effectiveness for managing plaque psoriasis.
What evidence suggests that this trial's treatments could be effective for psoriasis?
This trial will compare Deucravacitinib and Ustekinumab for treating plaque psoriasis. Research has shown that Deucravacitinib, which participants in this trial may receive, effectively treats moderate to severe plaque psoriasis. Studies found that about 72.1% of patients experienced significant improvement in their skin condition after one year, with this improvement remaining strong over five years. The treatment has demonstrated safety and effectiveness over time. Meanwhile, Ustekinumab, another treatment option in this trial, is well-known for treating psoriasis and has been widely used with good results. Both treatments aim to reduce the severity of psoriasis, but Deucravacitinib has shown promising long-term results in recent studies.13567
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for individuals with plaque psoriasis. Specific eligibility criteria are not provided, but typically participants would need a confirmed diagnosis and may be required to meet certain health standards.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Deucravacitinib or Ustekinumab to evaluate long-term safety
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Deucravacitinib
- Ustekinumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania